{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-24-000758","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.795777+00:00","generated_at":"2026-06-02T05:04:04.974980+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anavex Q2 FY2024 net loss $10.5M, cash $139.4M; blarcamesine EMA submission underway","bullets":["Net loss of $10.5M ($0.13/share) vs $13.1M loss ($0.17/share) in prior-year quarter.","Cash and equivalents $139.4M at Mar 31, 2024; estimated ~4-year runway at current burn rate.","R&D expenses $9.7M, G&A $2.8M; no revenue as clinical-stage biopharma.","Marketing Authorisation application for blarcamesine (Alzheimer's) submitted to EMA; FDA guidance supports single cognitive endpoint.","First cohort fully enrolled in ANAVEX3-71 Phase 2 schizophrenia trial; Phase 2b/3 Alzheimer's data to be published."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-24-000758","json":"https://secwatch.observer/filing/0001731122-24-000758.json","markdown":"https://secwatch.observer/filing/0001731122-24-000758.md","text":"https://secwatch.observer/filing/0001731122-24-000758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000758/0001731122-24-000758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000758/e5655_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:04:04.974980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"390734c4f12aecde5408e6ee6f18f423bb78b19a","claim":"ANAVEX LIFE SCIENCES CORP. reported financial results for its fiscal quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Anavex Life Sciences Corp. (the “ Company ”) issued a press release reporting financial results for its fiscal quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112224000758/0001731122-24-000758-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its fiscal quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}